25 February 2016 
EMA/147980/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
TachoSil 
human thrombin / human fibrinogen 
On 25 February 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
TachoSil. The marketing authorisation holder for this medicinal product is Takeda Austria GmbH. 
The CHMP adopted a new indication as follows2: 
“TachoSil is indicated in adults for supportive sealing of the dura mater to prevent postoperative 
cerebrospinal leakage following neurological surgery”. 
For information, the full indication for TachoSil will be as follows: 
“TachoSil is indicated in adults for supportive treatment in surgery for improvement of 
haemostasis, to promote tissue sealing, and for suture support in vascular surgery where 
standard techniques are insufficient, and for supportive sealing of the dura mater to 
prevent postoperative cerebrospinal leakage following neurological surgery.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
